TY - JOUR T1 - Cell therapy for ARDS: efficacy of endobronchial versus intravenous administration and biodistribution of MAPCs in a large animal model JF - BMJ Open Respiratory Research JO - BMJ Open Resp Res DO - 10.1136/bmjresp-2018-000308 VL - 6 IS - 1 SP - e000308 AU - Nayra Cardenes AU - Paola Aranda-Valderrama AU - Jonathan P Carney AU - Jacobo Sellares Torres AU - Diana Alvarez AU - Ergin Kocyildirim AU - Julie A Wolfram Smith AU - Antony E Ting AU - Luigi Lagazzi AU - Zheming Yu AU - Scott Mason AU - Ernesto Santos AU - Brian J Lopresti AU - Mauricio Rojas Y1 - 2019/01/01 UR - http://bmjopenrespres.bmj.com/content/6/1/e000308.abstract N2 - Introduction Bone marrow-derived multipotent adult progenitor cells (MAPCs) are adult allogeneic adherent stem cells currently investigated clinically for use in acute respiratory distress syndrome (ARDS). To date, there is no agreement on which is the best method for stem cells delivery in ARDS. Here, we compared the efficacy of two different methods of administration and biodistribution of MAPC for the treatment of ARDS in a sheep model.Methods MAPC were labelled with [18F] fluoro-29-deoxy-D-glucose and delivered by endobronchial (EB) or intravenous route 1 hour after lipopolysaccharide infusion in sheep mechanically ventilated. PET/CT images were acquired to determine the biodistribution and retention of the cells at 1 and 5 hours of administration.Results The distribution and retention of the MAPC was dependent on the method of cell administration. By EB route, PET images showed that MAPC remained at the site of administration and no changes were observed after 5 hours, whereas with intravenous route, the cells had broad biodistribution to different organs, being the lung the main organ of retention at 1 and 5 hours. MAPC demonstrated an equal effect on arterial oxygenation recovery by either route of administration.Conclusion The EB or intravenous routes of administration of MAPC are both effective for the treatment of ARDS in an acute sheep model, and the effect of MAPC therapy is not dependent of parenchymal integration or systemic biodistribution. ER -